Innate antimicrobial immunity in inflammatory bowel diseases.

Julia Beisner, Eduard F Stange, Jan Wehkamp

Dr Margarete Fischer-Bosch-Institute of Clinical Pharmacology, Stuttgart and University of Tübingen, Germany.

Journal Article: Expert Review of Clinical Immunology 09/2010; 6(5):809-18. DOI: 10.1586/eci.10.56

Abstract

Inflammatory bowel diseases are characterized by chronic intestinal inflammation at different sites. Data from animal models as well as human patients including gene-association studies suggest that different components of the innate barrier function are primarily defective. These recent advances support the evolving hypothesis that intestinal bacteria induce inflammation predominantly as a result of a weakened innate mucosal barrier in genetically predisposed individuals. This article discusses our current understanding of the primary events of disease. Together, these findings should result in new therapeutic avenues aimed at restoring antimicrobial barrier function to prevent a bacterial-triggered inflammatory response.

Source: PubMed

Comments on this publication

ResearchGate members can add comments. Sign up now and post your comment!

Similar publications

Science & Research Jobs

Keywords

antimicrobial barrier function
 
article discusses
 
bacterial-triggered inflammatory response
 
chronic intestinal inflammation
 
current understanding
 
genetically predisposed individuals
 
Inflammatory bowel diseases
 
innate barrier function
 
intestinal bacteria induce inflammation
 
new therapeutic avenues
 
recent advances support
 
weakened innate mucosal barrier